Effects of erenumab on migraine aura frequency: a REFORM study
Abstract
Background: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies effectively prevent migraine headache, but their impact on aura is unclear. The aim of this study was to characterize longitudinal changes in migraine aura frequency during and after preventive treatment with erenumab in adults with frequent, prospectively confirmed migraine aura.
Methods: This prospective, longitudinal, single-center investigation enrolled adults diagnosed with migraine with aura who reported ≥ 4 monthly migraine days and ≥ 2 monthly aura days during a 4-week baseline period. Erenumab was administered subcutaneously at a dose of 140 mg every 4 weeks for 24 weeks, followed by a 12-week post-treatment follow-up period. Headache and aura outcomes were recorded prospectively using standardized headache diaries completed throughout baseline, treatment, and follow-up. The primary outcome consisted of the mean absolute change in monthly aura days from baseline, evaluated at four-week intervals across the study period.
Results: Eighty participants with migraine with aura provided outcome data eligible for analysis. The mean (SD) age was 43.1 (11.9) years, and 74 participants (93%) were female. At baseline, participants reported a mean of 8.0 (SD, 5.1) monthly aura days. After 24 weeks of treatment, the mean change in monthly aura days was - 4.9 (95% CI, - 5.8 to - 4.0) compared to baseline (p < 0.001). This improvement was partially sustained during the subsequent 12-week post-treatment…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 74 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.